A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Clinical trial NCT05678270 · RECRUITING

Trial details

NCT number: NCT05678270
Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Intrahepatic Cholangiocarcinoma (ICC)

Start date: 2022-11-15
Primary completion: 2026-05-01
Enrollment: 70

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.